A detailed history of Invesco Ltd. transactions in Omeros Corp stock. As of the latest transaction made, Invesco Ltd. holds 34,401 shares of OMER stock, worth $256,631. This represents 0.0% of its overall portfolio holdings.

Number of Shares
34,401
Previous 37,472 8.2%
Holding current value
$256,631
Previous $152,000 10.53%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$3.54 - $5.47 $10,871 - $16,798
-3,071 Reduced 8.2%
34,401 $136,000
Q2 2024

Aug 13, 2024

BUY
$3.04 - $4.23 $2,441 - $3,396
803 Added 2.19%
37,472 $152,000
Q1 2024

May 14, 2024

SELL
$2.88 - $4.89 $16,476 - $27,975
-5,721 Reduced 13.5%
36,669 $126,000
Q4 2023

Feb 12, 2024

SELL
$1.08 - $3.63 $26,087 - $87,682
-24,155 Reduced 36.3%
42,390 $138,000
Q3 2023

Nov 13, 2023

BUY
$2.81 - $5.69 $94,348 - $191,047
33,576 Added 101.84%
66,545 $194,000
Q2 2023

Aug 11, 2023

BUY
$4.45 - $7.57 $146,712 - $249,575
32,969 New
32,969 $179,000
Q4 2022

Feb 13, 2023

BUY
$1.75 - $3.96 $21,234 - $48,050
12,134 New
12,134 $27,000
Q2 2022

Aug 15, 2022

SELL
$1.92 - $6.28 $51,482 - $168,391
-26,814 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$5.07 - $7.2 $410 - $583
-81 Reduced 0.3%
26,814 $161,000
Q4 2021

Feb 14, 2022

SELL
$5.67 - $8.54 $11,969 - $18,027
-2,111 Reduced 7.28%
26,895 $173,000
Q3 2021

Nov 15, 2021

BUY
$13.4 - $16.3 $61,345 - $74,621
4,578 Added 18.74%
29,006 $400,000
Q2 2021

Aug 17, 2021

BUY
$14.81 - $19.13 $137,466 - $177,564
9,282 Added 61.28%
24,428 $363,000
Q1 2021

May 17, 2021

BUY
$14.52 - $23.53 $42,195 - $68,378
2,906 Added 23.74%
15,146 $270,000
Q4 2020

Feb 16, 2021

BUY
$10.14 - $15.19 $124,113 - $185,925
12,240 New
12,240 $174,000

Others Institutions Holding OMER

About OMEROS CORP


  • Ticker OMER
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,730,000
  • Market Cap $468M
  • Description
  • Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical program...
More about OMER
Track This Portfolio

Track Invesco Ltd. Portfolio

Follow Invesco Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.